ASR Vermogensbeheer N.V. Acquires 6,049 Shares of Cencora, Inc. $COR

Key Points

• ASR Vermogensbeheer N.V. increased its Cencora stake by 26.9% in the fourth quarter, buying 6,049 additional shares and bringing its total holdings to 28,552 shares worth about $9.64 million.
• Cencora reported mixed quarterly results: EPS came in at $4.75, below estimates of $4.82, while revenue of $78.36 billion also missed expectations, though revenue still rose 3.9% year over year.
• Management signaled confidence by raising FY2026 EPS guidance to $17.65-$17.90 and resuming a $1 billion share repurchase program, even as analysts cut price targets but mostly kept bullish ratings.

ASR Vermogensbeheer N.V. lifted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 26.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 28,552 shares of the company's stock after purchasing an additional 6,049 shares during the period. ASR Vermogensbeheer N.V.'s holdings in Cencora were worth $9,643,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in COR. Marshall Wace LLP boosted its stake in Cencora by 518.9% in the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company's stock valued at $623,534,000 after acquiring an additional 1,672,762 shares in the last quarter. Mizuho Markets Americas LLC boosted its position in shares of Cencora by 116.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company's stock worth $66,506,000 after purchasing an additional 1,511,906 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company's stock worth $461,250,000 after buying an additional 1,241,186 shares during the last quarter. Viking Global Investors LP increased its position in Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company's stock valued at $624,207,000 after buying an additional 1,013,913 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Cencora by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company's stock valued at $7,311,810,000 after buying an additional 916,506 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on COR shares. Robert W. Baird dropped their price objective on shares of Cencora from $420.00 to $339.00 and set an "outperform" rating on the stock in a report on Thursday. Citigroup dropped their price target on Cencora from $405.00 to $355.00 and set a "buy" rating on the stock in a research note on Thursday. Jefferies Financial Group raised Cencora from an "underperform" rating to a "buy" rating in a report on Thursday, January 22nd. UBS Group raised their price objective on Cencora from $410.00 to $412.00 and gave the stock a "buy" rating in a research note on Thursday. Finally, Morgan Stanley set a $342.00 target price on Cencora in a research report on Friday. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $388.42.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora raised FY2026 EPS guidance to $17.65-$17.90 and resumed a $1 billion share repurchase program, signaling management confidence in earnings power and capital returns.
• Positive Sentiment: Several Wall Street firms still maintained bullish ratings after cutting price targets, including Citi and Baird, suggesting analysts continue to see upside despite the selloff.
• Neutral Sentiment: Commentary around the stock emphasizes a “valuation debate” and whether the post-earnings decline was overdone, indicating investors are reassessing expectations rather than reacting to a new operational shock. Cencora NYSE Composite Reset Sparks Valuation Debate
• Neutral Sentiment: Analyst and media coverage is also centered on margin expansion versus growth, reflecting debate over whether Cencora is prioritizing profitability and buybacks over top-line momentum. Is Cencora (COR) Prioritizing Margin Expansion Over Growth With Its Raised EPS Outlook and Buybacks?
• Negative Sentiment: The main bearish driver is the earnings report, which missed EPS estimates and came with sales below analyst expectations, raising concerns about near-term growth momentum. Cencora NYSE: COR reports sales below analyst estimates in Q1 CY2026 earnings
• Negative Sentiment: A securities fraud investigation announcement could add overhang and legal-risk concerns, potentially worsening sentiment until more details are known. Securities Fraud Investigation Into Cencora, Inc. (COR) Announced

Cencora Stock Up 2.2%

COR stock opened at $261.16 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.51. The company has a market cap of $50.80 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.64. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a fifty day moving average price of $327.81 and a 200 day moving average price of $342.26.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.Cencora's quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the company posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts expect that Cencora, Inc. will post 17.62 earnings per share for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora's payout ratio is presently 28.85%.

Cencora Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.